Recent Updates
Recently added Catalysts
LIVN Positive Sentiment

Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: LivaNova PLC announced the publication of the 36-month results from the CORE-VNS study, which evaluated the long-term effectiveness of VNS Therapy for Drug-Resistant Epilepsy. The study demonstrated sustained and increasing benefits for patients. This marks a significant contribution to the understanding of VNS Therapy's impact on epilepsy management.

Market Sentiment Analysis

POSITIVE FACTORS

  • Published long-term results from CORE-VNS study.
  • Demonstrated sustained benefits of VNS Therapy.
  • First long-term effectiveness evaluation for DRE.
  • Published in a reputable journal.

Full Press Release Details

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has published the full 36-month results from the CORE-VNS study, the first long-term effectiveness evaluation of contemporary VNS Therapy™ devices in people with Drug-Resistant Epilepsy (DRE). The article, “CORE-VNS Seizure and Non-Seizure 36 Month Outcomes in People with Drug-resistant Epilepsy,”1 re

Frequently Asked Questions

What are the CORE-VNS study results?

The CORE-VNS study published 36-month results showing sustained benefits of VNS Therapy.

What condition does VNS Therapy target?

VNS Therapy targets Drug-Resistant Epilepsy (DRE).

Where were the study results published?

The results were published in the journal Neuromodulation.

What is the significance of the CORE-VNS study?

It is the first long-term effectiveness evaluation of VNS Therapy devices.

ShareAdd on Google
Tags: LIVN LivaNova VNS Therapy Drug-Resistant Epilepsy CORE-VNS study neuromodulation
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$517M liquidity · $0M/mo burn
Low dilution risk
Lead asset
REPLY 200Phase 3
Bradycardia →